Search

Skin Irritation and Sensitization In Vitro Test

Creative Biolabs provides in vitro skin irritation and sensitization testing for topical live biotherapeutic and postbiotic candidates, helping teams detect cytotoxic, inflammatory, irritant, and sensitizing potential in use-relevant models and build a practical non-animal safety package. We integrate sample preparation, dose design, validated endpoints, controls, risk classification, and decision-ready reporting.

Topical LBP Safety Starts with Use-Relevant Skin Models

Topical live biotherapeutics, microbial lysates, fermentation-derived materials, and postbiotic preparations can interact with the skin barrier in ways that depend on viability, vehicle, concentration, contact time, and intended use. Early programs therefore need more than a generic cytotoxicity result: they need a coherent testing strategy that distinguishes reversible local irritation from immune-mediated sensitization potential across candidate selection, formulation development, and broader preclinical safety planning.

Human keratinocyte cultures, reconstructed epidermis, and immune-relevant cell systems provide complementary evidence while supporting animal-replacement goals. Creative Biolabs provides a tailored in vitro skin irritation and sensitization service that connects sample preparation, model selection, controls, mechanistic endpoints, and risk interpretation to the practical decisions facing skin microbiome and topical LBP developers.

Laboratory evaluation of topical live biotherapeutic samples in skin test models

What Are Skin Irritation and Skin Sensitization?

Both outcomes may involve redness or inflammation, but they arise through different biological processes and require distinct evidence streams.

Skin Irritation Skin Sensitization
A local, generally reversible response following skin contact. Barrier disruption, cell stress, cytotoxicity, and innate inflammatory signaling may contribute to redness, discomfort, itching, or pain at the exposure site. An acquired immune response in which exposure can initiate molecular and cellular events leading to allergic contact dermatitis after subsequent contact. Protein reactivity, keratinocyte activation, and dendritic-cell activation are key mechanistic events.
Typical evidence: tissue viability, barrier integrity, morphology, cytotoxicity, and inflammatory mediators. Typical evidence: peptide reactivity, ARE-Nrf2 signaling, cell-surface activation markers, viability, and integrated weight-of-evidence interpretation.

Skin is a multilayered protective organ that limits exposure to environmental hazards. For preclinical evaluation of topical products, it is important to identify candidates that may compromise this barrier or initiate allergic inflammation. A fit-for-purpose combination of human-relevant in vitro models can generate decision-ready safety evidence while reducing reliance on animal testing.

Skin Irritation and Sensitization In Vitro Test Services

Creative Biolabs builds testing combinations around the candidate form, intended topical exposure, and development question. Available systems include monolayer human or animal keratinocyte cultures, multilayer 3D skin models with barrier function, and co-culture approaches containing two or more skin-relevant cell types.

I

In Vitro Skin Irritation Test

We assess whether a topical candidate causes acute, local damage under defined exposure and recovery conditions. Study design can align with established reconstructed human epidermis logic and can be adapted for complex biological matrices after compatibility review.

Methods and frameworks

  • Reconstructed human epidermis test methods aligned with OECD TG 439
  • ET-50 and skin irritation test approaches
  • ISO 10993-23-aligned irritation considerations, where applicable
  • USP <88> biological reactivity testing context, when relevant

Readouts

Cell or tissue viability, cytotoxicity, barrier integrity, morphology, exposure-response behavior, and optional inflammatory mediators such as IL-1α, IL-6, IL-8, or other project-relevant cytokines.

S

In Vitro Skin Sensitization Test

Sensitization is addressed through complementary assays mapped to early mechanistic events rather than treated as a synonym for irritation. We help select an evidence set that fits the sample and supports an integrated hazard interpretation.

Methods and frameworks

  • Direct Peptide Reactivity Assay (DPRA), aligned with OECD TG 442C
  • ARE-Nrf2 luciferase methods, aligned with OECD TG 442D
  • Human Cell Line Activation Test (h-CLAT), aligned with OECD TG 442E
  • ISO 10993-10-aligned sensitization considerations, where applicable

Readouts

Peptide depletion, reporter activation, CD54 and CD86 expression, cytotoxicity controls, concentration-response patterns, and an assay-by-assay interpretation of sensitization potential.

Sample Preparation and Dose Design

Living organisms and postbiotic matrices may introduce turbidity, color, pH shifts, metabolic activity, or direct assay interference. We evaluate these factors before the definitive study and define a preparation method that preserves the intended test article while protecting endpoint interpretability.

  • • Direct application, suspension, extract, supernatant, lysate, or finished formulation
  • • Concentration range, exposure duration, recovery period, and vehicle controls
  • • Viable count or mass-based normalization where appropriate
  • • Positive, negative, solvent, and matrix controls selected for the assay
Planning Item Typical Requirement
Solid samples Two complete samples, each greater than 150 cm² or 10 g
Liquid samples 30 mL or more
Turnaround time Typically 8–10 weeks after protocol and sample acceptance
Final output A final study report with methods, controls, results, interpretation, and risk classification

Exact sample quantity can vary with matrix, assay combination, replicates, and confirmatory work. Submit project details early so feasibility and material needs can be reviewed before shipment.

Download the Sample Submission Form

In Vitro Skin Safety Testing Workflow

A staged workflow resolves matrix compatibility early, protects study validity, and connects each endpoint to a clear development decision.

01

Scope

Confirm product form, use scenario, safety question, and acceptance logic.

02

Prepare

Define sample handling, dose range, exposure, vehicle, and normalization.

03

Qualify

Run range-finding and interference checks; verify controls and model suitability.

04

Test

Execute the irritation or sensitization assay set with defined replicates and QC.

05

Interpret

Integrate endpoints, grade risk, document limitations, and recommend next steps.

Skin Irritation and Sensitization Test Report Deliverables

The reporting package is structured to help teams make formulation, dose, candidate-selection, and follow-on safety decisions without losing the assumptions behind the result.

Study Design Record

Test article handling, model rationale, exposure conditions, controls, replicates, and endpoint methods.

Quality-Control Summary

Control performance, assay validity, interference findings, deviations, and data-quality considerations.

Integrated Results

Tables and figures covering viability, activation, inflammatory, and concentration-response results.

Risk Interpretation

Irritation or sensitization classification, uncertainty notes, risk ranking, and practical next-step recommendations.

Published Data Support Reconstructed Epidermis Irritation Testing

Comparison of capacitance and cell viability predictions in reconstructed human epidermis. (OA Literature)
Fig.1 QileX-RhE normalized capacitance after 42 h at 17 kHz versus relative viability after 42 h. 1,2

Recent research evaluated chemical irritation using a reconstructed human epidermis model and compared a non-destructive capacitance readout with relative tissue viability. The published data indicate that barrier-related electrical measurements can distinguish irritant from non-irritant exposures and can be followed over multiple recovery times, while viability provides an established endpoint for tissue damage. This matters because topical safety decisions are stronger when exposure design, tissue response, and assay controls are interpreted together.

The figure shows how the two readout strategies separated reference substances after exposure, illustrating the value of orthogonal endpoints when one measurement may be affected by sample properties. For complex live biotherapeutic, lysate, or postbiotic matrices, that principle supports early interference assessment and a carefully selected endpoint panel. Creative Biolabs can translate this evidence logic into a fit-for-purpose irritation and sensitization program with compatible controls, mechanistic readouts, transparent risk interpretation, and practical follow-up recommendations.

Advantages of Creative Biolabs' In Vitro Skin Testing

Our testing strategy combines biological relevance with practical development planning for topical live biotherapeutic and postbiotic products.

Model-to-Use Alignment

We match monolayer, reconstructed tissue, or immune-relevant systems to the intended route, contact conditions, and product form instead of applying one generic assay to every sample.

Complex-Matrix Planning

Range-finding, interference controls, viability normalization, and vehicle selection help manage the analytical challenges created by living cells, microbial components, and colored or turbid formulations.

Decision-Ready Interpretation

We connect individual results to a transparent risk classification and explain what the evidence supports, where uncertainty remains, and which follow-on study would add the most value.

Expandable Biological Depth

When the project requires deeper mechanism insight, cellular phenotyping, inflammatory mediators, transcriptomic endpoints, and bioinformatics can extend the core safety interpretation.

Plan a Skin Safety Test Around Your Product

Share the candidate format, formulation, intended exposure, and current safety data so our team can recommend a focused assay combination and sample plan.

Frequently Asked Questions

Irritation testing assesses direct, local, generally reversible tissue damage after exposure. Sensitization testing evaluates mechanistic events associated with the development of an allergic immune response. Because the outcomes are biologically distinct, a topical safety strategy may need separate but complementary assays.

Potentially, but feasibility depends on the strain, formulation, growth behavior, intended exposure, and endpoint. A preliminary compatibility review can determine whether direct application, an extract, conditioned medium, lysate, or another test-article preparation is most interpretable.

We use feasibility work, range-finding, matrix-matched controls, and orthogonal readouts where appropriate. These steps help identify optical, chemical, or metabolic interference before it compromises a definitive viability, reporter, cytokine, or flow-cytometry result.

Human cell and reconstructed tissue methods can provide relevant non-animal evidence for defined irritation and sensitization questions. Suitability depends on the product, intended claim, jurisdiction, and decision context, so the assay combination and limitations should be established during study planning.

Please provide the product form, strain or material description, formulation and vehicle, storage conditions, intended topical use, expected exposure level and duration, available cytotoxicity data, and the development decision the study must support. This information helps us confirm feasibility and sample quantity.

Other Resources

Creative Biolabs Live Biotherapeutics service brochure

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic strain products for next-generation probiotic research brochure

Probiotic Strain Products for NGP Research - Brochure

Custom small-scale probiotic production brochure

Custom Small-scale Probiotic Production - Brochure

Creative Biolabs live biotherapeutics video

Live Biotherapeutics - Creative Biolabs - Video

References

  1. Chacón, Manuel, et al. "Improved tool for predicting skin irritation on reconstructed human epidermis models based on electrochemical impedance spectroscopy." Biosensors 13.2 (2023): 162. https://doi.org/10.3390/bios13020162
  2. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket